Participated · Series A · Jan 2026

Vitrealab is a Vienna-based spin-off from the Quantum Group at the University of Vienna that is building and manufacturing display components for AR glasses. Its core product, the Quantum Light Chip (QLC), is a photonic integrated circuit that houses hundreds of low-loss optical waveguides paired with nano-imprinted micro-optics and multiple RGB laser diodes to generate uniform, collimated light. This micro-scale light engine is intended to dramatically improve brightness and efficiency in AR displays. With its proprietary chip architecture, the company targets partnerships with AR headset manufacturers and other optical component suppliers. The firm plans to use newly raised funds to accelerate QLC development, broaden market reach, and deepen collaborations with industry partners. Founded in 2018 by Chiara Greganti, Jonas Zeuner, and Nobel laureate Anton Zeilinger, Vitrealab is currently led by CEO Ronny Timmreck. Financial details beyond the latest capital injection were not disclosed in the article.

Participated · Series A · Aug 2024

VSParticle develops nanoparticle synthesis and deposition tools, notably the VSP-P1 Nanoprinter, that let researchers produce nanoparticles and new materials with a button push. Its technology aims to compress material discovery timelines from as long as 15 years to about one year by enabling high-throughput experimentation and integration with autonomous labs using robotics and AI. Over the past year VSP shipped VSP-P1 units to customers in Asia, the Middle East, Europe, and North America, including Sorbonne University Abu Dhabi, Lawrence Livermore National Laboratory, MDRI, and the Dutch Institute for Fundamental Energy Research. The printers can mass-produce catalyst-coated porous transport layers (PTLs) for electrolyzers and are predicted to deliver up to tenfold savings in scarce metals such as iridium. VSP expects the first components developed using its technology to reach the market by 2027. The company positions itself at the forefront of the self-driving lab revolution, enabling AI-driven automation and high-throughput synthesis for energy and nanotechnology applications. VSParticle develops nanoparticle printing tools and services that break materials down to the size of nanoparticles and enable production for research and commercial R&D. Its core product set is aimed at accelerating material development to power next‑generation products. The technology is applicable across multiple industries, starting with the production of Catalyst Coated Membranes (CCM) for sustainable hydrogen innovations and next‑generation gas sensors. The company has built relationships in the CCM and precious metal markets, including with Heraeus Precious Metals, to support its launch of production tools. Management plans to scale up production of its tools and expand operations and commercial teams using the recent financing. VSParticle was founded in 2014 and was born out of decades of materials‑science research at TU Delft.

Participated · Series C · Mar 2023

Palo Alto–based Mythic has developed Analog Processing Units (APUs) that collapse compute and memory into a single plane, achieving around 120 TOPS-per-watt—roughly 100 × the energy efficiency of top-tier GPUs—even when moving data. The chips, already in production and validated by the U.S. DoD, major auto OEMs and defense contractors, target four trillion-dollar markets: data centers, automotive, robotics and defense, while also scaling to 1-trillion-parameter large language models. Internal benchmarks show up to 750× more tokens-per-second-per-watt and as much as an 80× cost advantage per million tokens versus NVIDIA’s highest-end GPUs. Beyond standalone APUs, Mythic is commercializing “Starlight” sub-1 W sensing modules that integrate its compute-in-memory technology directly into image sensors for 50× performance gains in low-light scenarios. The company offers a mature CAMP SDK that supports ONNX, PyTorch and TensorFlow and has been rated best-in-class among compute-in-memory peers. Led by former NVIDIA executive Taner Ozcelik, Mythic’s roadmap includes enabling ChatGPT-class models to run locally on handheld devices at roughly 1/100th today’s cost. The recent $125 million raise gives the firm substantial runway to scale manufacturing and expand its product portfolio.

Participated · Equity · Oct 2021

TriLite designs and manufactures the Trixel® 3, which it bills as the world’s smallest projection display using Laser Beam Scanning (LBS) technology. The Trixel® 3 targets AR smart glasses, OEM/ODM integrations, and in-vehicle driver information systems. The company emphasizes a compact form factor that enables high brightness and image performance for both consumer AR and automotive use cases. TriLite holds multiple patents around its projection technology and plans to refine its IP while scaling mass production. Management says the latest funding will accelerate production and innovation. The company is based in Vienna, Austria and was founded in 2011; prior to the new round it had reported total raises of $9.29M. TriLite, based in Vienna and led by CEO Peter Weigand, develops ultra-compact projection displays for consumer augmented and mixed reality applications. Its Trixel® 3 module occupies just 0.92 cm3 and combines a micro-optical RGB laser light source with a MEMS mirror to deliver bright, high-quality images at very low power consumption. The company has invested in software, including proprietary calibration algorithms, to simplify developer adoption and minimize optical system size and complexity. TriLite also offers a manufacturing platform and high-volume supply chain to accelerate customers' time-to-market. The firm's stated aim is to help AR/MR glasses overcome the bulkiness and weight that have hindered mass-market adoption. In October 2021 TriLite raised €8m to continue expanding operations and broaden its business reach.

Participated · Equity · Nov 2016

Immagina Biotechnology has developed a patented technology called RiboLace that enables users to better understand cellular function, with applications in personalized medicine research. Its products can be acquired by research labs and pharmaceutical companies to develop drugs that modify RNA gene expression. The company is advancing studies in cancer and neurodegenerative diseases. Immagina intends to use the recently raised funds to continue developing its technology. Founded in 2014 by Massimiliano Clamer following research at the University of Trento’s Center for Integrated Biologics and CNR‑IBF, the company is based in Trento, Italy. The report does not disclose operating metrics such as revenue or user numbers.